gto2 Antibody

What is the role of GOT2 in cancer cell metabolism and immune evasion?

Methodologically, researchers investigating GOT2's role should consider:

• CRISPR-Cas9 knockout models (sgGot2) to assess tumor growth in immunocompetent mice

• Time-course experiments to quantify intratumoral T-cell frequencies

• Immunophenotyping of tumor microenvironment using flow cytometry

• Antibody-based depletion of CD4+ and CD8+ T cells to determine immune-dependent effects

Interestingly, GOT2 depletion in PDAC models results in:

• Reduced tumor growth

• Increased CD8+ and CD4+ T-cell infiltration

• Changes in macrophage and dendritic cell populations

• T cell-dependent tumor growth suppression that can be reversed via T-cell depletion

What are the fundamental principles of anti-GD2 antibody function in neuroblastoma treatment?

Anti-GD2 antibodies target disialoganglioside GD2, a surface antigen highly expressed on neuroblastoma cells. Their therapeutic efficacy is primarily mediated through:

• Direct binding to GD2-expressing neuroblastoma cells with high affinity

• Recruitment of immune effector cells, particularly natural killer (NK) cells

• Induction of antibody-dependent cellular cytotoxicity (ADCC)

• Complement-dependent cytotoxicity (CDC)

Methodologically, researchers should evaluate anti-GD2 antibodies through:

• Flow cytometry to confirm binding to GD2-expressing cells

• ADCC assays using human NK cells and GD2-positive neuroblastoma cells

• Western blotting to confirm antibody secretion and structure

• In vivo studies using appropriate neuroblastoma models

Recent innovations include mesenchymal stem cells engineered to produce anti-GD2 antibodies (anti-GD2-MSCs). These cells demonstrated >90% transduction efficiency and produced functional antibodies that bind to GD2 antigen on neuroblastoma cells and induce ADCC-mediated cytotoxicity .

How do mesenchymal stem cells enhance antibody delivery in cancer therapeutics?

Mesenchymal stem cells (MSCs) offer significant advantages as delivery vehicles for therapeutic antibodies in cancer treatment:

For researchers working with MSCs as antibody delivery vehicles, the following methodological considerations are crucial:

• MSC isolation and characterization: Validate stem cell markers (CD29+, CD44+, CD90+) while confirming absence of hematopoietic markers (CD34-, CD45-)

• Genetic modification approaches: Lentiviral transduction offers high efficiency for antibody gene delivery as demonstrated in anti-GD2-MSC development

• Transduction assessment: Monitor expression via reporter genes (e.g., GFP) and quantify antibody secretion through Western blotting with appropriate tags (e.g., FLAG tag)

• Functional validation: Confirm antibody binding capacity through flow cytometry and ADCC assays with appropriate target cells

What are the standard methodologies for detecting GOT2 localization in cells?

GOT2 has been traditionally considered a mitochondrial protein, but recent evidence indicates nuclear localization in certain cancer contexts. To accurately detect GOT2 localization:

• Subcellular fractionation with Western blotting

  • Separate nuclear, mitochondrial, and cytosolic fractions

  • Use validated fraction-specific markers as controls (e.g., VDAC for mitochondria, histone H3 for nucleus)

  • Detect GOT2 with specific antibodies

• Immunofluorescence microscopy

  • Fix cells with paraformaldehyde (typically 4%)

  • Permeabilize with appropriate detergents (0.2% Triton X-100)

  • Co-stain with organelle markers (MitoTracker for mitochondria, DAPI for nucleus)

  • Use confocal microscopy for precise co-localization analysis

• Proximity ligation assay (PLA)

  • Detect protein-protein interactions between GOT2 and nuclear proteins

  • Quantify interaction signals across subcellular compartments

• CRISPR-based tagging

  • Endogenously tag GOT2 with fluorescent proteins

  • Perform live-cell imaging to track localization dynamically

Research has revealed that in PDAC cells, GOT2 exhibits both mitochondrial and nuclear localization, with the nuclear pool potentially mediating its interaction with PPARδ and subsequent effects on transcriptional regulation and immune suppression .

How does the GOT2-PPARδ interaction influence immune suppression in the tumor microenvironment?

The GOT2-PPARδ interaction represents a novel mechanism by which cancer cells evade immune surveillance. This interaction involves:

• Direct binding between GOT2 and fatty acid ligands that regulate PPARδ

• GOT2-mediated enhancement of PPARδ transcriptional activity

• Altered immunomodulatory gene expression profiles

• Subsequent changes in immune cell recruitment and function

Research methodologies to study this interaction should include:

• Chromatin immunoprecipitation (ChIP) assays to assess PPARδ binding to target promoters

• Transcriptional reporter assays using PPARδ response elements

• Co-immunoprecipitation to confirm GOT2-PPARδ physical interaction

• Structure-based mutagenesis of GOT2's fatty acid binding domains

• Assessment of T-cell infiltration and function in response to GOT2/PPARδ manipulation

Experimentally, GOT2 depletion in PDAC models leads to:

• Increased CD8+ T-cell infiltration into tumors

• Enhanced T-cell-mediated tumor control

• Altered myeloid cell populations, including increased cDC1 and proliferating macrophages

• T cell-dependent suppression of tumor growth that is reversed upon T-cell depletion

These findings indicate that targeting the GOT2-PPARδ axis may represent a novel approach to enhance immunotherapy efficacy in cancers like PDAC.

What experimental approaches can be used to study GOT2's fatty acid binding properties?

GOT2's recently discovered fatty acid binding function can be investigated through multiple complementary approaches:

• Structural analysis:

  • Crystal structure analysis to identify hydrophobic binding pockets

  • Molecular docking simulations to predict fatty acid binding sites

  • Site-directed mutagenesis of predicted binding residues

• Direct binding assays:

  • Isothermal titration calorimetry (ITC) to measure binding thermodynamics

  • Surface plasmon resonance (SPR) to assess binding kinetics

  • Fluorescent fatty acid analog binding assays

  • Thermal shift assays to evaluate protein stability changes upon ligand binding

• Functional validation:

  • Luciferase reporter assays with PPARδ response elements

  • Transcriptomic analysis after GOT2 manipulation

  • Structure-function studies with GOT2 mutants lacking fatty acid binding

Research has identified five putative fatty acid binding sites in GOT2 based on hydrophobicity analysis of its crystal structure. These sites may mediate GOT2's ability to regulate PPARδ activity, suggesting GOT2 functions as a fatty acid transport protein in addition to its established role as a transaminase .

How can researchers distinguish between GOT2's metabolic and transcriptional regulatory functions?

Distinguishing between GOT2's dual roles requires careful experimental design:

Key methodological strategies include:

• Domain-specific mutations:

  • Generate GOT2 mutants with impaired enzymatic activity but intact fatty acid binding

  • Create GOT2 variants with disrupted fatty acid binding but normal enzymatic function

• Subcellular targeting:

  • Express GOT2 with nuclear localization or export signals

  • Restrict GOT2 to mitochondria to assess specifically metabolic functions

• Temporal analyses:

  • Acute vs. chronic GOT2 inhibition to separate immediate metabolic effects from longer-term transcriptional changes

  • Time-course experiments after GOT2 activation or inhibition

What are the latest findings on GOT2 nuclear localization in cancer cells?

Recent research has revealed unexpected nuclear localization of GOT2 in cancer cells, particularly in PDAC, challenging the traditional view of GOT2 as exclusively mitochondrial. Key findings include:

• A significant pool of GOT2 localizes to the nucleus in:

  • Murine premalignant pancreatic lesions

  • Established pancreatic ductal adenocarcinoma

  • Human PDAC specimens

• Nuclear GOT2 appears to function distinctly from mitochondrial GOT2:

  • Associates with nuclear receptor PPARδ

  • Influences transcriptional programs

  • Affects immunomodulatory gene expression

• Experimental manipulation of GOT2 nuclear localization:

  • Adding nuclear localization signals enhances immune suppression

  • Nuclear-targeted GOT2 reduces T-cell abundance in tumors

  • Wild-type GOT2 reconstitution restores immune suppression

Methodologically, researchers investigating nuclear GOT2 should employ:

• Subcellular fractionation with stringent nuclear purification

• Confocal immunofluorescence with z-stack imaging

• Co-localization studies with nuclear markers

• ChIP-seq to identify genomic binding sites

• Proximity ligation assays to confirm protein-protein interactions in the nuclear compartment

These findings suggest that nuclear GOT2 may represent a novel therapeutic target for enhancing immune responses in cancer.

What are optimal protocols for generating anti-GD2 antibody-producing mesenchymal stem cells?

Generating effective anti-GD2 antibody-producing mesenchymal stem cells (anti-GD2-MSCs) requires optimization at multiple steps:

• Antibody construct design:

  • Include single-chain fragment variable (scFv) against GD2

  • Add appropriate linker sequences for flexibility

  • Incorporate constant region fragments (e.g., human IgG1 Fc)

  • Consider adding detection tags (FLAG, GFP) for validation

• MSC isolation and culture:

  • Harvest from appropriate tissue sources (bone marrow, adipose)

  • Characterize using positive (CD73, CD90, CD105) and negative (CD34, CD45) markers

  • Maintain at low passage number to preserve differentiation potential

  • Culture in defined media without xenogenic components for clinical applications

• Genetic modification:

  • Lentiviral transduction offers high efficiency (>90% reported)

  • Use appropriate promoters (e.g., CMV, EF1α) for sustained expression

  • Include reporter genes (GFP) to assess transduction efficiency

  • Optimize multiplicity of infection (MOI) to minimize cellular toxicity

• Validation steps:

  • Confirm antibody secretion via Western blotting

  • Verify antibody binding to GD2+ target cells using flow cytometry

  • Assess functional activity through ADCC assays

  • Measure antibody production kinetics and stability over time

Recent research successfully developed anti-GD2-MSCs with >90% transduction efficiency that secreted antibodies capable of binding to GD2-expressing neuroblastoma cells and enhancing NK cell-mediated cytotoxicity, demonstrating the feasibility of this approach for targeted cancer therapy .

What controls should be included in antibody-dependent cellular cytotoxicity (ADCC) assays?

ADCC assays are critical for evaluating anti-GD2 antibody functionality. Comprehensive controls include:

Methodological considerations:

• Effector:target (E:T) ratio optimization:

  • Test multiple ratios (typically 5:1, 10:1, 20:1)

  • Higher ratios may mask subtle antibody effects

• Readout selection:

  • Chromium-51 release (gold standard but involves radioactivity)

  • LDH release (colorimetric, non-radioactive)

  • Flow cytometry with viability dyes

  • Real-time impedance-based methods

• NK cell source considerations:

  • Primary NK cells vs. NK cell lines (NK-92)

  • Donor variability assessment

  • Activation status standardization

• Statistical analysis:

  • Calculate percent specific lysis: (experimental lysis - spontaneous lysis)/(maximum lysis - spontaneous lysis) × 100

  • Perform multiple replicates (minimum triplicates)

  • Apply appropriate statistical tests (ANOVA with post-hoc analysis)

How can researchers evaluate the tumor-targeting efficiency of anti-GD2 antibodies in vivo?

Evaluating anti-GD2 antibody tumor targeting in vivo requires multifaceted approaches:

• Direct imaging methodologies:

  • Near-infrared fluorescence imaging with labeled antibodies

  • PET imaging using radioisotope-conjugated antibodies (89Zr, 124I)

  • SPECT imaging with 111In or 99mTc-labeled antibodies

  • Intravital microscopy for real-time visualization

• Biodistribution studies:

  • Harvest organs at various timepoints post-administration

  • Quantify antibody concentration using ELISA or radioisotope counting

  • Calculate tumor-to-normal tissue ratios

  • Perform immunohistochemistry on tissue sections

• Appropriate animal models:

  • Xenograft models using GD2+ neuroblastoma cell lines

  • Patient-derived xenografts (PDXs) for clinical relevance

  • Transgenic GD2-expressing models

  • Humanized mouse models for evaluating immune interactions

• Comparing delivery strategies:

  • Direct antibody administration vs. MSC-mediated delivery

  • Different administration routes (IV, intraperitoneal, intratumoral)

  • Single vs. multiple dosing regimens

  • Combination with enhancing agents (e.g., checkpoint inhibitors)

• Quantitative assessments:

  • Pharmacokinetic/pharmacodynamic (PK/PD) modeling

  • Area under the curve (AUC) for tumor exposure

  • Maximum tumor uptake (% injected dose/gram)

  • Circulation half-life determination

MSC-based delivery systems offer particular advantages for in vivo targeting due to their inherent tumor tropism. Studies have demonstrated MSC accumulation in neuroblastoma tumors using the tyrosine hydroxylase (TH)-MYCN mouse model, suggesting their potential as effective delivery vehicles for anti-GD2 antibodies .

What are recommended approaches for measuring anti-GD2 antibody binding affinity?

Accurate measurement of anti-GD2 antibody binding affinity is crucial for predicting in vivo efficacy:

• Surface Plasmon Resonance (SPR):

  • Gold standard for real-time, label-free binding kinetics

  • Measures association (kon) and dissociation (koff) rate constants

  • Calculates equilibrium dissociation constant (KD = koff/kon)

  • Requires purified GD2 antigen immobilized on sensor chips

  • Can assess binding under various buffer conditions

• Bio-Layer Interferometry (BLI):

  • Alternative optical technique for real-time binding analysis

  • Simpler setup than SPR with comparable data quality

  • Suitable for crude samples and high-throughput screening

  • Less sensitive to buffer changes and refractive index

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • Scatchard analysis from serial dilution binding curves

  • Accessible technique requiring standard laboratory equipment

  • Less precise than biophysical methods but higher throughput

  • Suitable for comparative studies across multiple antibodies

• Flow Cytometry:

  • Cell-based affinity determination using GD2+ cell lines

  • Calculates apparent KD from titration curves

  • Evaluates binding in physiological membrane context

  • Can simultaneously assess binding to different cell populations

• Isothermal Titration Calorimetry (ITC):

  • Measures thermodynamic parameters (ΔH, ΔS) in addition to KD

  • Provides complete binding profile without labeling

  • Requires relatively large amounts of purified materials

  • Offers insights into binding mechanism

For anti-GD2 antibodies specifically, researchers should:

• Compare binding to different GD2+ neuroblastoma cell lines

• Include GD2-negative controls to assess specificity

• Evaluate binding in the presence of serum to predict in vivo behavior

• Assess cross-reactivity with structurally similar gangliosides (GD1b, GD3)

How can computational models improve antibody specificity design?

Computational modeling has revolutionized antibody design by enabling precise control over specificity profiles:

• Biophysics-informed modeling approaches:

  • Integrate experimental data with structural predictions

  • Identify distinct binding modes for different antigens

  • Enable design of antibodies with customized specificity profiles

  • Disentangle binding preferences for chemically similar epitopes

• Key computational methodologies:

  • Machine learning algorithms trained on experimentally selected antibodies

  • Molecular dynamics simulations to predict binding energetics

  • Structure-based design focusing on complementarity-determining regions (CDRs)

  • Energy minimization of antibody-antigen complexes

• Practical implementation workflow:

  • Generate experimental data through phage display selection against target antigens

  • Sequence selected antibodies using high-throughput methods

  • Develop computational models that associate distinct binding modes with specific ligands

  • Use models to predict and generate novel antibody variants with desired specificity

Recent research demonstrates the power of this approach:

• Models trained on one ligand combination successfully predicted outcomes for other combinations

• Generated antibody variants not present in initial libraries but with specific binding profiles

• Successfully designed antibodies with both highly specific and cross-specific binding properties

• Mitigated experimental artifacts and biases in selection experiments

What high-throughput screening methods are most effective for antibody specificity assessment?

Several complementary high-throughput methods offer comprehensive specificity assessment:

Methodological best practices include:

• Multi-platform validation:

  • Combine selection-based methods with direct binding assays

  • Cross-validate hits using orthogonal techniques

  • Progress from in vitro to cell-based assays

• Reference standard inclusion:

  • Benchmark against well-characterized antibodies

  • Include positive and negative control antigens

  • Establish clear specificity thresholds

• Advanced data analysis:

  • Implement machine learning for pattern recognition

  • Apply statistical methods to identify significant binders

  • Develop visualization tools to map specificity landscapes

• Iterative optimization:

  • Design focused secondary libraries based on initial hits

  • Perform competitive selections against multiple targets

  • Combine rational design with experimental selection

How can researchers identify distinct antibody binding modes for similar epitopes?

Distinguishing antibody binding modes for similar epitopes requires sophisticated experimental and computational approaches:

• Structural characterization:

  • X-ray crystallography of antibody-antigen complexes

  • Cryo-electron microscopy for difficult-to-crystallize complexes

  • NMR spectroscopy for dynamics and weak interactions

  • Hydrogen-deuterium exchange mass spectrometry for epitope mapping

• Mutational analysis:

  • Alanine scanning of antibody CDRs

  • Epitope saturation mutagenesis

  • Chimeric antigen construction

  • Deep mutational scanning with display technologies

• Computational binding mode prediction:

  • Molecular dynamics simulations

  • Molecular docking with constraint-based refinement

  • Free energy perturbation calculations

  • Machine learning trained on experimental binding data

• Biophysical differentiation:

  • Differential scanning calorimetry to assess thermodynamic parameters

  • pH and salt dependence of binding

  • Temperature effects on association/dissociation kinetics

  • Competitive binding assays with reference antibodies

Recent research demonstrates the application of biophysics-informed models to:

• Differentiate binding modes associated with chemically similar ligands

• Disentangle complex binding preferences that cannot be experimentally isolated

• Identify key sequence positions that determine specificity

• Generate customized antibodies with either highly specific binding to individual targets or controlled cross-reactivity

What are the best practices for validating computationally designed antibodies?

Validating computationally designed antibodies requires rigorous experimental confirmation:

• Sequential validation pipeline:

  • Initial binding confirmation (ELISA, BLI, SPR)

  • Specificity profiling against related antigens

  • Functional assays relevant to intended application

  • Biophysical characterization (stability, aggregation)

  • In vivo validation in appropriate models

• Control inclusion:

  • Parent antibody from which designs were derived

  • Computationally designed non-binding variants

  • Commercially available reference antibodies

  • Random mutations of same magnitude as designed changes

• Specificity validation matrix:

  • Test against target antigen under various conditions

  • Evaluate binding to closely related antigens

  • Screen against tissue panels for off-target binding

  • Assess performance in complex biological samples

• Functional confirmation:

  • Application-specific activity assays

  • Complement activation assessment

  • Fc receptor binding studies

  • Cell-based potency assays

Recently, researchers validated computationally designed antibodies by:

• Generating antibodies from computational predictions not present in original libraries

• Testing binding against both target and off-target antigens

• Comparing experimental results with computational predictions

• Validating both highly specific and intentionally cross-reactive antibodies

This approach has successfully produced antibodies with customized specificity profiles, demonstrating the power of computational design when coupled with rigorous experimental validation.

What analytical approaches are recommended for interpreting antibody NGS data?

Antibody NGS data analysis requires specialized computational approaches:

• Primary data processing workflow:

  • Quality control and trimming of raw reads

  • Paired-end read assembly

  • Error correction using UMI (Unique Molecular Identifiers)

  • V(D)J gene assignment and annotation

  • CDR identification and extraction

• Advanced analysis strategies:

  • Clustering of related sequences (hierarchical, density-based)

  • Lineage tracing and phylogenetic analysis

  • Diversity and similarity metrics calculation

  • Statistical comparison between sample groups

  • Machine learning for pattern recognition

• Software solutions and pipelines:

  • Specialized antibody NGS platforms (e.g., Geneious Biologics)

  • Open-source toolkits (IMGT/HighV-QUEST, IgBLAST)

  • Custom analysis workflows using Python/R

  • Cloud-based computing for large datasets

• Validation approaches:

  • Technical replicates to assess reproducibility

  • Spike-in controls with known sequences

  • Orthogonal validation of key findings

  • Sensitivity analysis for parameter choices

Modern antibody NGS analysis platforms offer comprehensive solutions:

• Analysis of millions of antibody sequences in minutes

• Automated quality control, assembly, and annotation

• Sequence validation using customizable rule sets

• Advanced visualization and clustering capabilities

• Statistical tools for comparison across datasets

How can researchers effectively visualize antibody diversity and specificity profiles?

Effective visualization of antibody data enhances interpretation and communication:

• Sequence-level visualizations:

  • Logo plots for position-specific amino acid frequencies

  • Heat maps of CDR amino acid composition

  • Circular plots for V(D)J gene usage

  • Mutation frequency plots relative to germline

• Population-level analyses:

  • Dimensionality reduction (PCA, t-SNE, UMAP)

  • Hierarchical clustering dendrograms

  • Network graphs of sequence relationships

  • Diversity indices (Simpson, Shannon) with radar plots

• Specificity profile visualization:

  • Binding heat maps across multiple antigens

  • 3D surface plots of affinity landscapes

  • Radar plots of cross-reactivity profiles

  • Scatter plots of binding vs. specificity metrics

• Structural representations:

  • CDR loop conformations in 3D

  • Antibody-antigen interface contacts

  • Electrostatic surface potential maps

  • Molecular dynamics trajectory visualization

Modern antibody analysis platforms offer specialized visualization capabilities:

• Interactive sequence viewers for navigating large datasets

• Scatter plots for identifying outliers and distribution patterns

• Cluster visualization tools showing sequence relationships

• Amino acid composition plots to reveal variability patterns

• Heat maps to display relationships between genes in sequences

• Customizable histograms and bar charts for frequency analysis

Effective visualization strategies help researchers identify patterns and relationships that might be missed in tabular data, facilitating hypothesis generation and decision-making in antibody engineering efforts.

What statistical methods should be used to identify significant antibody variants in a library?

Identifying significant antibody variants requires robust statistical approaches:

• Enrichment analysis:

  • Calculation of enrichment ratios between selection rounds

  • Hypergeometric testing for over-representation

  • Fisher's exact test for count data

  • Negative binomial models for sequence counts

• Comparative statistics:

  • ANOVA for multi-group comparisons

  • Mann-Whitney U test for non-parametric comparisons

  • False discovery rate (FDR) correction for multiple testing

  • Confidence interval estimation for enrichment ratios

• Advanced statistical approaches:

  • Bayesian inference for probability estimation

  • Maximum likelihood estimation for parameter fitting

  • Poisson models for rare variant detection

  • Bootstrapping for robust confidence intervals

• Machine learning classification:

  • Support vector machines for binary classification

  • Random forests for feature importance ranking

  • Neural networks for complex pattern recognition

  • Clustering algorithms to identify related sequences

When applying these methods, researchers should:

• Establish appropriate null models and control distributions

• Account for library bias and technical artifacts

• Consider sequence abundance and sampling depth

• Integrate both statistical significance and effect size

• Validate findings across independent experiments or replicates

How can bioinformatics tools help optimize antibody specificity and affinity?

Bioinformatics tools offer powerful approaches for antibody optimization:

• Sequence-based prediction:

  • Machine learning models trained on experimental data

  • Position-specific scoring matrices for amino acid preferences

  • Statistical coupling analysis to identify co-evolving residues

  • Natural language processing approaches to sequence patterns

• Structure-based optimization:

  • Homology modeling of antibody variable domains

  • Molecular docking of antibody-antigen complexes

  • In silico alanine scanning to identify key residues

  • Free energy calculations to predict affinity changes

• Integrated platforms:

  • Antibody-specific databases (IMGT, abYsis, SAbDab)

  • Specialized antibody design software

  • Workflow management systems for computational pipelines

  • Cloud-based resources for computationally intensive tasks

• Emerging approaches:

  • Deep learning for antibody property prediction

  • Graph neural networks for structural representation

  • Generative models for novel antibody design

  • Reinforcement learning for multi-objective optimization

Recent research demonstrates how bioinformatics tools can:

• Identify distinct binding modes associated with specific ligands

• Disentangle complex binding preferences

• Generate antibodies with customized specificity profiles

• Design antibodies that were not present in experimental libraries

These approaches have successfully created antibodies with both highly specific binding to individual targets and controlled cross-reactivity across multiple targets .